Patent ID: 6803374
Filing Date: 2004-10-12
Classification: A61P,C07D

Abstract:
A compound of Formula I wherein:Q is N; R1 is tetrazolyl, MeCONHSO2â€”, PhCONHSO2â€”, R5O2C(CH2)0-3CONHSO2â€”, R2 is â€ƒâ€”CH2Ar1, â€”CHPh2, â€”CH2CO(4-FPh), â€”CH2CO(4-CF3Ph), or â€”CH2CONp where Np is naphthyl; R3 is C5-7cycloalkyl; R4 is hydrogen, Ar2, or Ar3; Ar1 is selected from the following group: phenyl, halophenyl, Ar2 is phenyl, naphthyl, or biphenyl, optionally substituted with 1-3 substituents selected from the group comprising halogen, C1-6 alkyl, hydroxyC1-6alkyl, C1-6alkoxy, C1-6sulfoxy, C1-2perfluoroalkyl, hydroxy, formyl, C1-6alkylcarbonyl, cyano, nitro, C1-6alkylamido, CO2R5, CONR5R5, C1-6alkylsulfonamido, and dioxolane; Ar3 is thienyl, furanyl, pyrrolyl, benzothiophenyl, benzofuranyl, indolyl, quinolinyl, or pyrimidinyl optionally substituted with 1-2 substituents selected from the group comprising C1-6alkyl, formyl, acetoxy, trifluoroacetoxy, and t-butoxycarbonyl; R5 is hydrogen or C1-6alkyl; R6 is halogen, methoxy, CO2R5 or CONR7R8; R7 and R8 are independently hydrogen, C1-6alkyl, â€”CH(Me)CO2R5, â€”(CH2)1-3CO2R5, â€”(CH2)1-3CONR5R5, â€”(CH2)1-3OH, â€ƒor R7 and R8 taken together with the nitrogen to which they are attached form pyrrolidine, morpholine, piperidine, 4-hydroxypiperidine, piperazine, or 4-methylpiperazine; or a pharmaceutically acceptable salt, solvate, or prodrug thereof.